Endogenous prostanoids and arterial contractility.

Prostaglandins Leukot Essent Fatty Acids

Department of Pharmacodynamics, Semmelweis University of Medicine, Budapest, Hungary.

Published: October 1988

Download full-text PDF

Source
http://dx.doi.org/10.1016/0952-3278(88)90169-xDOI Listing

Publication Analysis

Top Keywords

endogenous prostanoids
4
prostanoids arterial
4
arterial contractility
4
endogenous
1
arterial
1
contractility
1

Similar Publications

Metabolic pathways of eicosanoids-derivatives of arachidonic acid and their significance in skin.

Cell Mol Biol Lett

January 2025

Department of Analytical Chemistry, Medical University of Bialystok, Kilinskiego 1, 15-069, Bialystok, Poland.

The skin is a barrier that protects the human body against environmental factors (physical, including solar radiation, chemicals, and pathogens). The integrity and, consequently, the effective metabolic activity of skin cells is ensured by the cell membrane, the important structural and metabolic elements of which are phospholipids. Phospholipids are subject to continuous transformation, including enzymatic hydrolysis (with the participation of phospholipases A, C, and D) to free polyunsaturated fatty acids (PUFAs), which under the influence of cyclooxygenases (COX1/2), lipoxygenases (LOXs), and cytochrome P450 (CYPs P450) are metabolized to various classes of oxylipins, depending on the type of PUFA being metabolized and the enzyme acting.

View Article and Find Full Text PDF

The urothelium and lamina propria (LP) contribute to sensations of bladder fullness by releasing multiple mediators, including prostaglandins (PGs) and adenosine 5'-triphosphate (ATP), that activate or modulate functions of cells throughout the bladder wall. Mediators that are simultaneously released in response to bladder distention likely influence each other's mechanisms of release and action. This study investigated whether PGs could alter the extracellular hydrolysis of ATP by soluble nucleotidases (s-NTDs) released in the LP of nondistended or distended bladders.

View Article and Find Full Text PDF

Molecular basis of lipid and ligand regulation of prostaglandin receptor DP2.

Proc Natl Acad Sci U S A

December 2024

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Prostaglandin D2 receptor 2 (DP2) is an important anti-inflammatory and antiallergic drug target. While inactive DP2 structures are known, its activation mechanisms and biased signaling remain unclear. Here, we report cryo-EM structures of an apo DP2-Gi complex, a DP2-Gi complex bound to the endogenous ligand Prostaglandin D (PGD), and a DP2-Gi complex bound to indomethacin, an arrestin-biased ligand, at resolutions of 2.

View Article and Find Full Text PDF
Article Synopsis
  • The introduction of modulators, correctors, and potentiators for the CFTR molecule has significantly improved the health of most individuals with cystic fibrosis (CF).
  • While these therapies impact certain fatty acids, they do not address linoleic acid (LA) deficiency, which is linked to more severe forms of CF.
  • The review examines lipid abnormalities in CF patients, such as altered phospholipid and cholesterol levels, and their connection to clinical symptoms, revealing these lipid issues can manifest before birth.
View Article and Find Full Text PDF

Prostaglandin D2 (PGD2) signals via the DP1 and DP2 receptors. In Phase II trials, DP2 antagonism decreased airway inflammation and airway smooth muscle (ASM) area in moderate-to-severe asthma patients. However, in Phase III, DP2 antagonism failed to lower the rate of exacerbations, and DP2 as a target was shelved.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!